Hairy Cell Leukemia: Clinical Trials

19 trials for Hairy Cell Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 5 active not recruiting, 5 recruiting, 1 enrolling by invitation. 19 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 219Completed 6, Active not recruiting 5, Recruiting 5, Enrolling by invitation 1, Terminated 1, Withdrawn 1
Phase 13Completed 2, Recruiting 1
Phase 31Recruiting 1

Follow Hairy Cell Leukemia: new trials by email Literature Review of Hairy Cell Leukemia trials Research Report on Hairy Cell Leukemia

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Enrolling by invitationBnai Zion Medical Center122026-06-012026-07-08
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia
Phase 2RecruitingMemorial Sloan Kettering Cancer Center862024-09-092026-09-09
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Low dose vemurafenib plus rituximab - Hairy Cell Leukemia
Phase 2CompletedScripps Health152022-03-022026-04-24
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
binimetinib - Hairy Cell Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)402021-01-072026-10-16
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
binimetinib, Encorafenib - Hairy Cell Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)282020-10-282026-06-12
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2WithdrawnCity of Hope Medical Center2020-10-202020-12-17
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Vemurafenib, Obinutuzumab - Hairy Cell Leukemia, Leukemia
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center302018-02-092026-08-24
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia
Phase 1 / Phase 2CompletedAlexey Danilov, MD242017-07-172023-08-08
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL
Phase 1 / Phase 2CompletedAcerta Pharma BV1612015-02-202026-05-13
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Active not recruitingNational Cancer Institute (NCI)442013-04-302026-11-12
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Vemurafenib - Hairy Cell Leukemia
Phase 2CompletedMemorial Sloan Kettering Cancer Center362012-10-012025-10-20
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Pentostatin, Rituximab, Bendamustine - Hairy Cell Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)692010-07-012026-10-15
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
BL22 (CAT-3888) - Hairy Cell Leukemia
Phase 2TerminatedNational Cancer Institute (NCI)12009-02-012015-10-29
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Cladribine, Rituximab, BMbx - Hairy Cell Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)1752008-10-202026-08-18
LMB-2 to Treat Hairy Cell Leukemia
Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin - Hairy Cell Leukemia
Phase 2CompletedNational Cancer Institute (NCI)152006-05-022023-11-14
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Cladribine, Laboratory Biomarker Analysis, Rituximab - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center1502004-06-102026-06-11
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Cladribine s.c. injection, HCL treatment - Hairy Cell Leukemia
Phase 2 / Phase 3RecruitingUniversity of Giessen2102004-05-012024-08-22
A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
Roferon-A - Hairy Cell Leukemia
Phase 2CompletedNational Cancer Institute (NCI)561997-01-012008-03-04

Narrower conditions

Leukemia, Hairy Cell (19)  ·  Leukemia (3)  ·  Hematologic Neoplasms (2)  ·  Hodgkin Disease (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Follicular (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Neoplasm, Residual (2)  ·  Anemia (1)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Burkitt Lymphoma (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Prolymphocytic, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)

Broader conditions

Hematologic Diseases (19)  ·  Hemic and Lymphatic Diseases (19)  ·  Immune System Diseases (19)  ·  Immunoproliferative Disorders (19)  ·  Lymphatic Diseases (19)  ·  Lymphoproliferative Disorders (19)  ·  Neoplasms (19)  ·  Neoplasms by Histologic Type (19)  ·  Leukemia (16)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Chronic Disease (3)  ·  Disease Attributes (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphoma (3)

Interventions

Rituximab (6)  ·  Cladribine (4)  ·  Vemurafenib (4)  ·  obinutuzumab (3)  ·  Biopsy (2)  ·  CT-P10 (2)  ·  Specimen Handling (2)  ·  binimetinib (2)  ·  6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)  ·  Acetaminophen (1)  ·  Adrenal Cortex Hormones (1)  ·  B3(Fv)-PE38KDEL recombinant immunotoxin (1)  ·  Bendamustine Hydrochloride (1)  ·  Bronchodilator Agents (1)  ·  Caves (1)

Sponsors

National Cancer Institute (NCI) (9)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Acerta Pharma BV (1)  ·  Alexey Danilov, MD (1)  ·  Bnai Zion Medical Center (1)  ·  City of Hope Medical Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  Scripps Health (1)  ·  University of Giessen (1)

Countries

United States (16)  ·  Germany (1)  ·  Israel (1)

Top investigators

Robert J Kreitman, M.D. (6)  ·  Jae Park, MD (2)  ·  Alan Saven, MD (1)  ·  Craig Okada, M.D. (1)  ·  Farhad Ravandi-Kashani (1)  ·  Ibrahim Aldoss, MD (1)  ·  Jae H. Park, MD (1)  ·  Kerry A Rogers (1)  ·  Mathias J Rummel, Prof. Dr. (1)  ·  Seema A Bhat (1)

Results publications

PMID 18596230, PMID 21821712, PMID 26352686, PMID 32109194, PMID 33754642, PMID 34196037, PMID 34607348, PMID 35930750, PMID 38320179, PMID 41060318, PMID 42308249

NIH funding

UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), U01CA076576 (1)